Jean Tang, M.D., Ph.D. is co-founder of PellePharm and serves on the PellePharm board of directors.
Jean is a practicing dermatologist and associate professor of dermatology at Stanford University. Her research focuses on finding new ways to treat and prevent non-melanoma skin cancer and genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. Jean and her colleagues discovered that hedgehog pathway inhibition could dramatically shrink basal cell carcinoma tumors in patients with Gorlin Syndrome in randomized clinical trials. She has led or co-led four investigator-initiated clinical trials, three of which were focused on basal cell carcinoma treatment or prevention.
Jean earned both her M.D. and Ph.D. from Stanford University. She completed her dermatology residency at Stanford and later completed a three-year post-doctorate in mouse genetics at the University of California, San Francisco while simultaneously pursuing formal coursework in biostatistics, epidemiology and clinical trial design.